Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 15, 2002

View Archived Issues

Inhibitors of AChE and BuChE with trypsin-activating effects for use in AD

Novel GH secretagogues identified at Sumitomo

Procyon presents new protein kinase C modulators for inflammation and psoriasis

Sumitomo researchers describe hypolipidemic compounds with LDL receptor-upregulating activity

Novel agents for urinary incontinence covered by Boehringer Ingelheim patent

New factor Xa inhibitors in development at Lilly

MMP inhibitors for use in cancer, COPD, asthma and brain edema prepared at Novartis

Pregabalin reported to improve GAD symptoms

Kos files sNDA for Niaspan for reducing risk of stroke

Potential use of metyrapone as an adjunct in major depression

Additional data on atomoxetine in ADHD discussed in Barcelona

Possible new indications for gabapentin

Thuris and D-Pharm initiate feasibility project

M-Vax and O-Vax INDs cleared

Adenosine A2A receptor agonist promotes wound healing: topical CGS-21680 effective in mice

YM-598 effective against diabetic nephropathy in a rat model of type 2 diabetes

NF-kB decoy oligodeoxynucleotide prevents and induces regression of atopic dermatitis in mice

Ciclosporin-loaded microspheres assessed for efficacy and safety in corneal rejection model

Naturally produced antibiotic is a promising anti-TB drug candidate

Conformationally constrained oxazolidinones evaluated for SAR

Potential antibacterial agents from PanTherix target chorismate synthase

First PDF inhibitor enters human testing; several ICAAC presentations cover these novel agents

Avandamet approved for type 2 diabetes

Lipitor shows significant benefit in reducing heart attacks and stroke in ASCOT trial

Celera Diagnostics and Bristol-Myers Squibb collaborate on cardiovascular disease and diabetes

Epidex receives humanitarian use device designation

Approvable letter for Vanlev